Eligible patients were randomly assigned in a @:@ ratio to transcatheter aortic valve replacement with the self-expanding transcatheter valve ( transcatheter aortic valve replacement -LSB- TAVR -RSB- group ) or to aortic valve replacement with a surgical bioprosthesis ( surgical group ) .